Citations

Clear

3138 citation(s) found for "Smith, AM".

Abstract P2098: The Interaction of Vascular Risk Factors in Midlife and Late-life on Incident Dementia: The Atherosclerosis Risk in Communities Neurocognitive Study
Gottesman, Rebecca F., Palta, Priya , Windham, B. Gwen , Coresh, Josef, Sharrett, A. Richey , Gross, Alden L. , Smith, Jason A. , Pike, James Russell , Lutsey, Pamela L. , Selvin, Elizabeth , Knopman, David S. , Deal, Jennifer A.

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p2098 Get It

Introduction: Vascular risk factors of hypertension, diabetes, and smoking in midlife (45-64 years) and possibly early late-life (65-74 years) are associated with increased risk of dementia. Current estimates of population attributable risk for dementia assume vascular factors are independent and do not interact to increase risk of dementia, which may underestimate the combined impact of vascular risk reduction on dementia incidence. In this study, we evaluated the joint association and interaction of vascular risk factors on risk of dementia. Methods: We performed a prospective cohort analysis using the Atherosclerosis Risk in Communities Neurocognitive Study using up to 33 years of follow-up (1987-2020). We used age as baseline (45-54 years, n=7,731; 55-64 years, n=12,273; and 65-74 years, n=6,660). We defined hypertension as systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥80 mm Hg, or anti-hypertension medication use. We defined diabetes as fasting glucose level ≥126 mg/dL, non-fasting glucose ≥200 mg/dL, self-reported physician diagnosis, or use of any diabetes medication. Current smoking was self-reported. We investigated additive and multiplicative interactions for combinations of vascular risk factors on incident (adjudicated) dementia by age 80 using joint effect variables in Cox regression models stratified by age of risk factor measurement (45-54 years, 55-64 years, or 65-74 years). For interaction analyses, parameter values >1 indicate positive interaction (synergy) and values <1 indicate negative interaction (antagonism). Results: In participants with risk factors measured in these baseline age strata, there were 801 (10%), 995 (8%), and 422 (6%) cases of incident dementia by age 80, respectively. Hypertension and diabetes exhibited positive interactions on the additive and multiplicative scales in midlife (Figure 1). Diabetes and smoking in midlife had positive additive interaction (value >1, Figure 2). All vascular risk factor combinations in late-life had negative interactions on the multiplicative scale (values <1, Figures 1-3). Conclusions: Hypertension with diabetes and diabetes with smoking, all measured in midlife, interact to increase risk of dementia by age 80. The overall impact of reducing midlife vascular risk factors on incident dementia could be sizeable. These findings highlight the importance of multifactor interventions addressing combinations of vascular risk factors for dementia prevention strategies.
Abstract P2088: Impact Of Geographic Residence And Treatment Modality On Mortality Outcomes Among Adult Patients Diagnosed With Acute Myocardial Infarction
Smith, Carlton, Xu, Liou , Dixon, Debra , Haynes, Norrisa , Onwuanyi, Anekwe , Olafiranye, Oladipupo , Puckrein, Gary A. , Adedinsewo, Demilade

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p2088 Get It

Background: In the United States, rural residents face unique challenges that affect their overall cardiovascular health and mortality including access to care for acute cardiovascular conditions. We assessed differences in mortality and mode of care among adult patients diagnosed with acute myocardial infarction (AMI) based on geographical residence. Methods: Using data from the Medicare Provider Analysis and Review files, we identified adult patients aged 45 and older who were diagnosed with AMI between 2015 and 2019. Cox-proportional hazards regression models were constructed to determine the association between patient’s geographic residence (rural vs. urban) on 30- and 90-day all-cause mortality. Results: A total of 868,955 adult patients diagnosed with AMI were included in this study. Twenty-six percent of the sample resided in rural areas. Among rural residents with AMI, 46% were managed invasively with either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery which was similar to 45% of urban residents. After controlling for age, race, sex, and comorbid conditions, rural residents had a higher risk of death compared to urban patients (aHR 1.04, p<0.001) at 30 and 90 days. In subgroup analyses, a similar pattern was observed among those who did not undergo invasive procedures (aHR 1.06, p<0.001), however, there was no differences in mortality at 30 days (aHR 0.99, p=0.30) and 90 days (aHR: 0.99, p=0.36) between rural and urban residents who were managed by PCI or CABG. Conclusion: Rural patients with AMI had a higher mortality risk than their urban counterparts, and this difference was driven by a higher death rate among those managed conservatively. Further investigation is needed to understand the underlying factors driving rural-urban disparities in mortality, particularly with non-invasive management of AMI.
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study
Balte, Pallavi , Sun, Yifei , Allen, Nori, Arynchyn, Alexander , Bowler, Russell P. , Elkind, Mitchell S, Garcia‐Bedoya, Olga , Garudadri, Suresh , Hansel, Nadia N. , Hermann, E.A. , Hoffman, Eric A. , Kaplan, Robert C. , Laine, Andrew F. , Lynch, David A. , Matsushita, Kunihiro , McKleroy, William , Naik, Sneha N. , O'Driscoll, O., Rusk, A.M., Salvatore, Mary , Smith, Benjamin M. , Sotres‐Alvarez, Daniela , Umans, Jason G. , Washko, George R. , Woodruff, Prescott G. , Ortega, Victor E. , Oelsner, Elizabeth C. , Balte, Pallavi P , Bowler, Russell P , San Jose Estepar, Raul , Hoffman, Eric A , Humphries, Stephen M , Krishnan, Jerry A , Podolanczuk, Anna J , Rusk, Annie, Wenzel, Sally E , Oelsner, Elizabeth C , Kim, John S. , Allen, Nori, Angelini, Elsa D. , Barr, R. Graham , Blaha, Michael Joseph , Carr, J. Jeffrey , Cole, Shelley A. , Couper, David , Demmer, Ryan T. , Doyle, Margaret F. , Estépar, Raúl San Jośe , Humphries, Stephen M. , Hunninghake, Gary M. , Lee, Joyce , Make, Barry J. , Min, Yuan‐I , O’Connor, George T. , Oren, Eyal , Podolanczuk, Anna J. , Post, Wendy S. , Pottinger, Tess D. , Regan, Elizabeth Anne , Schwartz, David A. , Vasan, Ramachandran S. , Wenzel, Sally E. , Xanthakis, Vanessa

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 16, 2025 | Volume: 211 | Issue: 7 | Pages: 1196-1210

10.1164/rccm.202408-1656oc | PMID 40238945 Get It

Abstract Rationale Increased risk of coronavirus disease (COVID-19) hospitalization and death has been reported among patients with clinical lung disease. Objectives To test the association of objective measures of prepandemic lung function and structure with COVID-19 outcomes in U.S. adults. Methods Prepandemic obstruction (FEV1/FVC &lt; 0.70) and restriction (FEV1/FVC ⩾ 0.7, FVC &lt; 80%) were defined based on the most recent spirometry exam conducted in 11 prospective U.S. general population–based cohorts. Severe obstruction was classified by FEV1 &lt; 50%. Percentage emphysema, percentage high-attenuation areas, and interstitial lung abnormalities were defined on computed tomography in a subset. Incident COVID-19 was ascertained via questionnaires, serosurvey, and medical records from 2020 to 2023 and classified as severe (hospitalized or fatal) or nonsevere. Cause-specific hazard models were adjusted for sociodemographics, anthropometry, smoking, comorbidities, and COVID-19 vaccination status. Measurements and Main Results Among 29,323 participants (mean age, 67 yr), there were 748 severe incident COVID-19 cases over median follow-up of 17.3 months from March 1, 2020. Greater hazards of severe COVID-19 were associated with severe obstruction (vs. normal; adjusted hazard ratio [aHR], 2.11; 95% confidence interval [CI], 1.02–1.27), restriction (vs. normal; aHR, 1.40; 95% CI, 1.12–1.76), and percentage emphysema (highest vs. lowest quartile; aHR, 1.64; 95% CI, 1.03–2.61), but not greater high-attenuation areas or interstitial lung abnormalities. COVID-19 vaccination provided greater absolute risk reduction in these groups. Results were similar in participants without smoking, obesity, or clinical cardiopulmonary disease. Conclusions Prepandemic severe spirometric obstruction, spirometric restriction, and greater percentage emphysema lung on computed tomography were associated with risk of severe COVID-19. These findings support enhanced COVID-19 risk mitigation for individuals with impaired lung health and warrant further mechanistic studies on interactions of lung function, structure, and vulnerability to acute respiratory illnesses.
Autologous Transplant or CAR‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments
Furqan, Fateeha , Ahn, Kwang Woo , Kaur, Manmeet , Patel, Jinalben , Ansell, Stephen M. , Awan, Farrukh T. , Baird, John H. , Farooq, Umar , Fung, Henry C., Khurana, Arushi , Lekakis, Lazaros J. , Lutfi, Forat , McCarty, John M. , Mukherjee, Akash , Nath, Rajneesh , Winter, Allison , Sauter, Craig S. , Herrera, Alex F. , Smith, Melody , Ansell, Stephen M , Baird, John , Khurana, Arushi , Winter, Allison , Shadman, Mazyar , Herrera, Alex F , Awan, Farrukh T , Smith, Melody , Bezerra, Evandro D. , Farooq, Umar, Romancik, Jason T. , Schuster, Stephen J. , Smith, Melody , Turtle, Cameron J. , Shadman, Mazyar , Hamadani, Mehdi

Mayo Clinic

American Journal of Hematology | April 15, 2025 | Volume: 100 | Issue: 7 | Pages: 1152-1162

10.1002/ajh.27687 | PMID 40231369 Get It

ABSTRACTAlthough recent studies have demonstrated the efficacy of chimeric antigen receptor T‐cell (CAR‐T) therapy in relapsed large B‐cell lymphoma (LBCL) with MYC rearrangement (R‐MYC), the data comparing CAR‐T to autologous hematopoietic cell transplant (auto‐HCT) in such patients who achieve a complete or partial response (CR/PR) after salvage therapies are limited. We compared the clinical outcomes of patients with R‐MYC LBCL (including double and triple hit lymphomas) who underwent CAR‐T or auto‐HCT after achieving a CR/PR with salvage therapies using the Center for International Blood & Marrow Transplant Research registry. Among the 252 patients (auto‐HCT = 98, CAR‐T = 154), relative to auto‐HCT, CAR‐T was associated with significantly lower overall survival (OS) (Hazard Ratio [HR] 2.09, 95% CI 1.38–3.15, p < 0.001) on multivariate analysis. There were no differences in progression‐free survival (PFS) (HR 1.21, 95% CI 0.81–1.8 p = 0.36), risk of relapse (HR 1.1, 95% CI 0.71–1.69 p = 0.68), nonrelapse mortality (NRM) (HR 1.74, 95% CI 0.64–4.7 p = 0.28) while the post‐relapse survival was longer in auto‐HCT relative to CAR‐T (HR 1.93, 95% CI 1.21–3.06 p = 0.01). On propensity score matched analysis accounting for differences in characteristics across the two cohorts, we detected no significant differences in OS (HR 1.72, 95% CI 0.92–3.21 p = 0.09), PFS (HR 1.04, 95% CI 0.64–1.68 p = 0.88), NRM (HR 1.22, 95% CI 0.35–4.2 p = 0.76), relapse (HR = 0.93, 95% CI 0.54–1.6 p = 0.8) and post‐relapse survival (HR 2.25, 95% CI 0.98–5.17, p = 0.06). These data, although retrospective, support consideration for auto‐HCT in patients with R‐MYC LBCL who achieve a CR/PR after salvage therapies, particularly in regions with no or limited access to CAR‐T.
Regulatory T Cell Mimicry by a Subset of Mesenchymal GBM Stem Cells Suppresses CD4 and CD8 Cells
Johnson, Amanda , Korleski, Jack , Sall, Sophie , Li, Yunqing , Zhou, Weiqiang , Smith-Connor, Karen, Laterra, John , López-Bertoni, Hernando , Johnson, Amanda L , Korleski, Jack , Sall, Sophie , Li, Yunqing , Zhou, Weiqiang , Lopez-Bertoni, Hernando , Khela, Harmon Singh

Mayo Clinic

Cells | April 14, 2025 | Volume: 14 | Issue: 8 | Pages: 592

10.3390/cells14080592 | PMID 40277917 Get It

Attempts to activate an anti-tumor immune response in glioblastoma (GBM) have been met with many challenges due to its inherently immunosuppressive tumor microenvironment. The degree and mechanisms by which molecularly and phenotypically diverse tumor-propagating glioma stem cells (GSCs) contribute to this state are poorly defined. In this study, our multifaceted approach combining bioinformatics analyses of clinical and experimental datasets, single-cell sequencing, and the molecular and pharmacologic manipulation of patient-derived cells identified GSCs expressing immunosuppressive effectors mimicking regulatory T cells (Tregs). We showed that this immunosuppressive Treg-like (ITL) GSC state is specific to the mesenchymal GSC subset and is associated with and driven specifically by TGFβ type II receptor (TGFBR2) in contrast to TGFBR1. Transgenic TGFBR2 expression in patient-derived GBM neurospheres promoted a mesenchymal transition and induced a six-gene ITL signature consisting of CD274 (PD-L1), NT5E (CD73), ENTPD1 (CD39), LGALS1 (galectin-1), PDCD1LG2 (PD-L2), and TGFB1. This TGFBR2-driven ITL signature was identified in clinical GBM specimens, patient-derived GSCs, and systemic mesenchymal malignancies. TGFBR2high GSCs inhibited CD4+ and CD8+ T cell viability and their capacity to kill GBM cells, effects reversed by pharmacologic and shRNA-based TGFBR2 inhibition. Collectively, our data identify an immunosuppressive GSC state that is TGFBR2-dependent and susceptible to TGFBR2-targeted therapeutics.
Noninvasive brain stimulation as focal epilepsy treatment in the hospital, clinic, and home
Islam, Karimul , Starnes, Keith , Smith, Kelsey M. , Gregg, Nicholas M. , Worrell, Gregory A. , Lundstrom, Brian N. , Richner, Thomas, Gregg, Nicholas M , Worrell, Gregory A , Lundstrom, Brian Nils , Smith, Kelsey M , Starnes, Donnie Keith , Islam, Karimul , Richner, Thomas J. , Rabinstein, Alejandro A.

Mayo Clinic

Epilepsia Open | April 10, 2025 | Volume: 10 | Issue: 3 | Pages: 787-795

10.1002/epi4.70033 | PMID 40208019 Get It

Abstract Objective Noninvasive brain stimulation (NIBS) provides a treatment option for patients not eligible for surgical intervention or who seek low‐risk approaches and may be used in the hospital, clinic, and at home. Our objective is to summarize our single‐center experience with multiple NIBS approaches for the treatment of focal epilepsy. Methods A retrospective chart review identified drug‐resistant focal epilepsy patients who received NIBS as an epilepsy treatment at Mayo Clinic in Rochester, MN. Patients were typically treated as follows: (1) for TMS, 1 Hz stimulation was applied for five consecutive days in the neuromodulation clinic, (2) for outpatient tDCS, stimulation was applied for five consecutive days in the clinic, followed by optional treatment at home, and (3) for inpatient tDCS, stimulation was applied for three consecutive days. We analyzed continuous EEG data for the inpatient tDCS cohort and available HD‐EEG data for outpatient cohorts to quantify changes in interictal epileptiform discharges (IEDs) as a result of stimulation. Outcomes were assessed at 1 month for TMS and outpatient tDCS and 1 week for inpatient tDCS. Results Twenty‐four patients were treated with TMS ( n = 10) and tDCS ( n = 14, 9 as outpatients). The median age was 40 years (range 15–73). The median seizure reduction following stimulation was 50%. Fourteen patients (58%) were responders to treatment (TMS = 4/10, tDCS Outpatient = 7/9, tDCS Inpatient = 3/5). Five outpatient tDCS participants elected to continue treatment at home. Four TMS and four outpatient tDCS patients underwent high‐density EEG before and after 5 days of therapy. Following stimulation, IED rate was reduced in 4/5 inpatient tDCS patients, 4/4 outpatient tDCS patients, and 4/4 TMS patients. Two patients experienced an increase in seizure frequency (1 following TMS and 1 following outpatient tDCS), which returned to baseline 4–6 weeks after stimulation treatments were discontinued. Significance TMS and tDCS are potential treatment approaches for drug‐resistant focal epilepsy patients in the hospital, clinic, and home. They have a favorable safety profile and can lead to a reduction in IED rates and seizures. These results suggest further studies are needed to examine NIBS as a treatment for epilepsy. Plain Language Summary Noninvasive brain stimulation, such as transcranial magnetic stimulation and transcranial direct current stimulation, offers new treatment options for patients with focal seizures. This study reviewed the experience at Mayo Clinic using noninvasive brain stimulation in the hospital, clinic, and at‐home settings to treat seizures. The results showed an overall 50% median seizure reduction, and 58% of patients had at least a 50% reduction in seizures. Noninvasive brain stimulation is a promising treatment approach with a favorable safety profile.
Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review
Grogan, Martha , López-Jiménez, Francisco , Guthrie, Spencer , Kumar, Nisith, Langevin, R.Eugene, Lousada, Isabelle , Witteles, Ronald , Royyuru, Ajay K. , Rosenzweig, Michael , Cairns‐Smith, Sarah , Royyuru, Ajay , Ouyang, David , Lopez-Jimenez, Francisco , Kumar, Nisith, Langevin, Reuben

Mayo Clinic

Journal of the American Heart Association | April 10, 2025 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/jaha.124.036533 | PMID 40207501 Get It

Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the performance of these tools is lacking. This narrative review of published literature describes the performance of AI tools that use data from ECGs and echocardiography to improve identification of CA and challenges that hinder adoption of these tools. Thirteen studies met inclusion criteria with sample sizes ranging from 50 to 2451 patients. Four studies used ECG data, 8 used echocardiography data, and 1 used both. The CA gold standard was typically defined as a CA diagnosis in an institutional or other database but the requirements for these diagnoses were heterogenous across studies, and many did not distinguish among CA subtypes. AI model development varied considerably, and only 4 studies included external validation. The ability of models to predict CA ranged from 0.71 to 1.00, sensitivity ranged from 16% to 100%, and specificity from 75% to 100%. Only 1 study reported model performance across strata of sex, age, race, and CA type. Persistent challenges to AI adoption include usability, cost, value added, electronic health record/information technology interoperability, patient‐related factors, regulation, and privacy and liability. Published studies on AI for improved identification of CA show favorable performance measures but numerous methodologic and other challenges must be addressed before these tools are more widely adopted.
Brain Perfusion Abnormalities using pCASL Imaging in Participants with Acute Post-Traumatic Headache due to Mild Traumatic Brain Injury (P4-12.005)
Nikolova, Simona , Li, Jing , Thomas, Aaron , Ross, Katherine , Smith, Dani, Leonard, Michael , Schwedt, Todd J. , Dumkrieger, Gina , Wu, Teresa , Zhou, Yuxiang , Leonard, Michael, Chong, Catherine D.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000209006 Get It

ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003)
Shuhaiber, Hans, Viskochil, David , Bielamowicz, Kevin , Lokku, Armend, Smith, L. Mary, Weintraub, Lauren , McNall‐Knapp, Rene , Hajjar, Fouad, Babovic‐Vuksanovic, Dusica , Moertel, Christopher L. , Hirbe, Angela C. , Sidhu, Alpa , Weber, Michael , Foreman, Nicholas K. , Gershon, Timothy R.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000209005 Get It

Neurocognitive Function and Psychiatric Comorbidities in Patients with Epilepsy with Eyelid Myoclonia (P7-9.002)
Padilla, Hannah, Alden, Eva , Snehal, Isha , Smith, Kelsey , Britton, Jeffrey W. , Wong‐Kisiel, Lily C. , Wirrell, Elaine , Smith, Kelsey

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210840 Get It